CN1056314A - Useful bacterial strain of one strain and application thereof - Google Patents
Useful bacterial strain of one strain and application thereof Download PDFInfo
- Publication number
- CN1056314A CN1056314A CN 90102847 CN90102847A CN1056314A CN 1056314 A CN1056314 A CN 1056314A CN 90102847 CN90102847 CN 90102847 CN 90102847 A CN90102847 A CN 90102847A CN 1056314 A CN1056314 A CN 1056314A
- Authority
- CN
- China
- Prior art keywords
- huaxing
- humber
- increase
- bacterial strain
- curative effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A kind of multi-functional Huaxing Humber 1 (BF839) bacterial strain that screening and separating goes out from well-developed baby or low-aged animal intestinal microflora, utilize fermentation technique to make viable bacteria system preparation, can increase upgrowth and development of children, control acute chronic enteritis, flora imbalance, upper respiratory tract infection and neurosis etc. all there are better curative effect, particularly remarkable to infantile diarrhea, malnutritive curative effect especially.Can increase livestock and poultry, the weight of animals, egg productivity and strengthen disease resistance as fodder additives, also can be used for preparing makeup, protective foods and beverage etc.
Description
The invention belongs to technical field of bioengineering, particularly relate to a kind of Huaxing Humber 1 (BF893) bacterial strain and application thereof that utilizes microbial fermentation technology to cultivate.
In recent years, American-European advanced country is engaged in the scholar of pathogeny microorganism, many people turn to the research to useful normal microorganism, adopt biotechnology to solve the problem that aspects such as agricultural, livestock industry, body-care, disease preventing and treating (comprise and capture the obstinate fort of cancer) and prolongs life exist.Through international online retrieval, the antitumor action document (J55092322,1978) that relates to bifidus bacillus is arranged, but do not see the report of this class strains separation of relevant Huaxing Humber 1 (BF839), cultivation and application.
The microecosystem of human body and immunity, metabolism, nutrition are relevant, decline along with this system of increase of year order is residual gradually and wear out, so the easy weak and easy cancer stricken of the people more than 60 years old less than the people of 60 years old strong shape is then denied.Purpose of the present invention is intended to isolate the probiotics that some plays an important role the microecosystem normal physiological bacterium in the low age human or animal body, be transplanted in the human or animal body at advanced age, make its recovery and set up the higher new microecosystem of biomass, improve field planting durability factor level, reach and recover or part is recovered the states such as nutrition, metabolism and immunity that low age is had period.
The present invention implements by following step: screen, isolate multi-functional Huaxing Humber 1 (BF839) bacterial strain from well-developed baby or low-aged animal intestinal microflora, utilize microbial fermentation technology to make active bacteria formulation, be used to cure multiple disease, preparation protective foods, beverage, drink additive and makeup etc.
Huaxing Humber 1 (BF839) is one of normal physiological anaerobic bacterium of human body, identify through Chinese science institute of microbiology and Inst. of Epidemiology and Microbiology, Chinese Academy of Preventive Medicine (, all tentatively be a kind in the bacteroides fragilis group (BacteroidesFragilis).Limit because of domestic equipment and condition, ultrastructure and some feature thereof of Huaxing Humber 1 (BF839) are not made the full conclusion in garden as yet.
Through nearly 10 years studies show that, this bacterium has following function: (1) improves body immunity, increases the immune t-cell activity; (2) help the absorption of human body digest food; (3) some toxicant in the degraded intestines; (4) get rid of alien bacteria and settle down, adjust intestinal flora and distribute at enteron aisle; (5) synthetic multivitamin and protein in enteric cavity; (6) anticancer growth etc.
Can increase upgrowth and development of children by hundreds of routine clinical verification Huaxing Humber 1s (BF839) preparation, control acute chronic enteritis, flora imbalance, upper respiratory tract infection and neurosis etc. all there are better curative effect, particularly remarkable to infantile diarrhea, malnutritive curative effect especially.Can increase poultry, the weight of animals, egg productivity and strengthen disease resistance as fodder additives, also can be used for preparing makeup, protective foods and beverage etc.
Huaxing Humber 1 (BF839) is to get from well-developed baby intestinal flora, puts in the anaerobically fermenting substratum of autogamy fermentation and makes active bacteria formulation.Anaerobically fermenting substratum composition: peptone 0.5~25%, glucose 0.2~0.5%, halfcystine 0.01~0.5%, Nac10.2~0.5%, Na
2HPO
40.1~0.3% sodium thioglycollate 0.02~0.1%, beef liver or pork liver immersion liquid 30~100% beef infusion broths 30~100%, yeast extract paste 0.1~0.8%.32~40 ℃ of ferment at constant temperature were cultivated 12~72 hours, and 3500 rev/mins of centrifugal supernatant liquors that go are surveyed bacterium and used.
Example one
Huaxing Humber 1 (BF839) is inoculated in the 10 liter anaerobically fermenting substratum, cultivated 24 hours for 37 ℃.Recording every milliliter of viable count is 2084 * 10
6=10
8.2(press log10
n/ ml calculates).3000~4000 rev/mins of centrifugal supernatant liquors that go, washing, diluted for use.
Example two
Huaxing Humber 1 (BF839) is inoculated in the 3 liter anaerobically fermenting substratum 37 ℃ cultivated 30 hours, recording every milliliter of viable count is 1132 * 10
7=10
9.1(press log10
nCalculate).3000~4000 rev/mins of centrifugal supernatant liquors that go, washing, diluted for use.
Example three
Huaxing Humber 1 (BF839) is inoculated in the 10 liter anaerobically fermenting substratum, cultivated 24 hours for 37 ℃, recording every milliliter of viable count is 588 * 10
8=10
9.8(press log10
nCalculate).3000~4000 rev/mins of centrifugal supernatant liquors that go, washing, diluted for use.
Example four
BF839 living bacterial liquid 10ml(viable count 4,000,000,000/ml) of early 10 minutes after the meal clothes was observed 11.5 months altogether next day of boarding at the nursery children in 3~6 years old for the kindergarten, and the result shows and takes height and the body weight (table 1,2) that the Bf839 living bacterial liquid has increased children significantly.
Table 1, child take body weight change result behind the BF839
Continue Time of Administration (moon) n
1(test group) n
2(control group) T value P value
2 64 54 2.50 <0.05
5 53 46 2.97 <0.01
7.5 59 56 3.58 <0.01
236 patients such as youngster's diarrhoea, amebic dysentery, depressive psychosis, bacillary dysentery, constipation every day early, service once the BF839 living bacterial liquid, each 20ml(viable count 4,000,000,000/ml), the efficient 98.3%(table 4 that reaches after the supper).
Table 4, take the curative effect of BF839 to intestinal tract disease
The example number each one take a bottle number (100nl/ bottle) rehabilitation take a turn for the better invalid
Chronic intestinal inflammations 81 1~10 746 1
Acute enteritis 17 1~3 17 2
Bowel dysfunction 22 1~6 164
General maldigestion 32 1~4 302
Liver property maldigestion 8 4~10 53
Senile maldigestion 6 3~10 6
Infantile diarrhea 58 1~3 58
Amebic dysentery 141
Depressive psychosis 33
Bacillary dysentery 44
Constipation 44
Sum 236 21,418 4
Percentage 100% 90.7% 7.6% 1.7%
Table 2, child take height result of variations behind the BF839
Continue Time of Administration (moon) n
1(test group) n
2(control group) T value P value
6 53 46 1.78 >0.05
11.5 44 46 2.90 <0.01
Example five
BF839 living bacterial liquid 10ml(viable count 4,000,000,000/ml) of early 10 minutes after the meal clothes next day of boarding at the nursery children in 3~6 years old for the kindergarten, blood sampling is measured the T cell with esterase staining after 11 months, and the result shows and takes the immunologic function (table 3) that the BF839 living bacterial liquid has significantly increased children.
Table 3, T raji cell assay Raji result
n
1(test group)
2(control group) T value P value
Group experiment 45 38 4.18<0.01
Pair test 30 30 3.25<0.01
Example six
Acute enteritis, cureless chronic intestinal inflammations (part is made a definite diagnosis through enteroscopy), bowel dysfunction, general that the standard routinely of giving is made a definite diagnosis, liver property and senile disappearing are estimated bad, baby
Example seven
BF839 living bacterial liquid 10ml(viable count 2,000,000,000/ml) of early 10 minutes after the meal clothes was observed 11.5 months altogether next day of boarding at the nursery children in 3~6 years old for the kindergarten, and the result shows that the BF839 living bacterial liquid has the effect (table 5) of prevention youngster respiratory tract disease.
Table 5, clothes BF839 are to the prophylactic effect of children's upper respiratory tract sense
Continue Time of Administration (moon) n
1(test group) n
2(control group) T value P value
11.5 63 55 3.12 <0.01
Example eight
With 120 of the poulty house laying hens that makes on the same day of the same race, with under the living condition, use forage feed of the same race at this, stochastic sampling is divided into each 60 of test group and control groups.Test group every day admixes in the feed feeding by the amount of every chicken clothes bacterium several 2,000,000,000 with the BF839 living bacterial liquid and suffers all, continue after 31 days trial periods and the drug withdrawal to observe 21 days, altogether in 52 days 60 laying hens of test group increase the 17.43Kg(table 6 of laying eggs than 60 laying hens of control group).
Table 6, BF839 increase the egg productivity of chicken
Gross weight (Kg) weight (the Kg)/sky of on average laying eggs of laying eggs, the average egg number (only) of the sum (only) of laying eggs/sky
Test group 2,379 45.75 143.09 2.7
Control group 2,124 40.85 125.56 2.42
Claims (3)
1, a kind of Huaxing Humber 1 bacterial strain (BF839), it is characterized in that this bacterium is that screening from well-developed baby or low-aged animal intestinal microflora, separation are provided multi-functional: improve body immunity, increase the immune t-cell activity, help the absorption of human body digest food, some toxicant in the degraded intestines is got rid of alien bacteria and is settled down at enteron aisle, adjusts intestinal flora and distributes, synthetic multivitamin and protein in enteric cavity, anticancer growth etc.This bacterium being inoculated in the anaerobically fermenting substratum of autogamy fermentation culture makes active bacteria formulation and can increase upgrowth and development of children, control acute chronic enteritis flora imbalance, upper respiratory tract infection and neurosis etc. all there are better curative effect, particularly remarkable to infantile diarrhea, malnutritive curative effect especially.Can increase livestock and poultry, the weight of animals, egg productivity and strengthen disease resistance as fodder additives, also can be used for preparing makeup, protective foods and beverage etc.
2,, it is characterized in that the anaerobically fermenting substratum that is inoculated in autogamy is made up of following compositions: peptone 0.5~25%, glucose 0.2~0.5%, halfcystine 0.01~0.5%, N by the described the sort of Huaxing Humber 1 bacterial strain of claim 1 (BF839)
aCl0.2~0.5%, N
aHP-O
40.1~0.3%, sodium thioglycollate 0.02~0.1%, beef liver or pork liver immersion liquid 30~100%, beef infusion broth 30~100%, yeast extract paste 0.1~0.8%.
3, by the described the sort of Huaxing Humber 1 bacterial strain of claim 1 (BF839), it is characterized in that this bacterium is inoculated in the anaerobically fermenting of autogamy, substratum fermentation culture 12~72 hours, thermostat temperature is 32~40 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 90102847 CN1029857C (en) | 1990-05-03 | 1990-05-03 | Preparation method of bacteroides microecological preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 90102847 CN1029857C (en) | 1990-05-03 | 1990-05-03 | Preparation method of bacteroides microecological preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1056314A true CN1056314A (en) | 1991-11-20 |
CN1029857C CN1029857C (en) | 1995-09-27 |
Family
ID=4877730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 90102847 Expired - Fee Related CN1029857C (en) | 1990-05-03 | 1990-05-03 | Preparation method of bacteroides microecological preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1029857C (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103120705A (en) * | 2013-01-21 | 2013-05-29 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating constipation |
CN103142658A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating acute radiation enteritis |
CN103142657A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia |
CN103142656A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer |
CN103156888A (en) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating inflammatory bowel diseases |
CN103156887A (en) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for promoting bifidobacterium and lactobacillus to grow |
CN103404707A (en) * | 2013-08-19 | 2013-11-27 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals |
CN105274019A (en) * | 2014-07-08 | 2016-01-27 | 王军 | Liquid-solid combined fermentation process for Bacteroides fragilis |
CN105434477A (en) * | 2015-10-29 | 2016-03-30 | 广州知易生物科技有限公司 | Application of bacteroides fragilis in resisting aquacultural pathogenic bacteria |
WO2019056404A1 (en) * | 2017-09-22 | 2019-03-28 | 中山大学 | Use of bacteroides fragilis in preparation of medicament for treating and preventing tumor |
CN110025636A (en) * | 2018-01-12 | 2019-07-19 | 广州知易生物科技有限公司 | Application of the bacteroides fragilis extract in the composition of preparation strengthen immunity |
CN110283760A (en) * | 2019-07-30 | 2019-09-27 | 集美大学 | A kind of fermentation culture method of common eel source bacteroides fragilis |
CN112587552A (en) * | 2020-09-17 | 2021-04-02 | 大连图腾生命科学发展有限公司 | Application of bacteroides fragilis839 in preparation of medicine and food for treating or assisting in treating immune-related diseases |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103082294A (en) * | 2013-01-21 | 2013-05-08 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating diarrhea |
CN103146620A (en) * | 2013-03-25 | 2013-06-12 | 广州知光生物科技有限公司 | Bacteroides fragilis with characteristics of probiotics |
CN109793761B (en) * | 2017-11-17 | 2021-03-05 | 瑞微(深圳)生物科技有限公司 | Composition for enhancing T cell immune function and preparation method thereof |
CN113151083B (en) * | 2021-04-21 | 2022-05-20 | 中国疾病预防控制中心传染病预防控制所 | Bacteroides dorsalis probiotics and application thereof in preparation of influenza treatment or prevention medicine |
-
1990
- 1990-05-03 CN CN 90102847 patent/CN1029857C/en not_active Expired - Fee Related
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103120705A (en) * | 2013-01-21 | 2013-05-29 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating constipation |
CN103142658A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating acute radiation enteritis |
CN103142657A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating hypercholesteremia |
CN103142656A (en) * | 2013-03-18 | 2013-06-12 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparing composition for preventing and treating colon cancer |
CN103156888A (en) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for treating inflammatory bowel diseases |
CN103156887A (en) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of composition for promoting bifidobacterium and lactobacillus to grow |
CN103404707A (en) * | 2013-08-19 | 2013-11-27 | 广州知光生物科技有限公司 | Application of bacteroides fragilis in preparation of compositions for preventing intestinal diseases of animals |
CN105274019A (en) * | 2014-07-08 | 2016-01-27 | 王军 | Liquid-solid combined fermentation process for Bacteroides fragilis |
CN105434477A (en) * | 2015-10-29 | 2016-03-30 | 广州知易生物科技有限公司 | Application of bacteroides fragilis in resisting aquacultural pathogenic bacteria |
WO2017071346A1 (en) * | 2015-10-29 | 2017-05-04 | 广州知易生物科技有限公司 | Applications of bacteroides fragilis in resistance against aquacultural pathogenic bacteria |
CN105434477B (en) * | 2015-10-29 | 2019-03-05 | 广州普维君健药业有限公司 | Application of the bacteroides fragilis in anti-aquatic pathogenic bacterium |
WO2019056404A1 (en) * | 2017-09-22 | 2019-03-28 | 中山大学 | Use of bacteroides fragilis in preparation of medicament for treating and preventing tumor |
CN110025636A (en) * | 2018-01-12 | 2019-07-19 | 广州知易生物科技有限公司 | Application of the bacteroides fragilis extract in the composition of preparation strengthen immunity |
CN110025636B (en) * | 2018-01-12 | 2021-07-23 | 石家庄普维生物科技有限公司 | Application of bacteroides fragilis extract in preparation of composition for enhancing immunity |
CN110283760A (en) * | 2019-07-30 | 2019-09-27 | 集美大学 | A kind of fermentation culture method of common eel source bacteroides fragilis |
CN112587552A (en) * | 2020-09-17 | 2021-04-02 | 大连图腾生命科学发展有限公司 | Application of bacteroides fragilis839 in preparation of medicine and food for treating or assisting in treating immune-related diseases |
CN112587552B (en) * | 2020-09-17 | 2023-09-12 | 大连图腾生命科学发展有限公司 | Application of bacteroides fragilis839 in preparing medicament for treating or assisting in treating immune related diseases |
Also Published As
Publication number | Publication date |
---|---|
CN1029857C (en) | 1995-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1029857C (en) | Preparation method of bacteroides microecological preparation | |
CN102093967B (en) | Mink source enterococcus faecium and application thereof | |
CN102041238B (en) | Lactobacillus plantarum, method for fermenting and preparing bacteriocin of Lactobacillus plantarum, and application of Lactobacillus plantarum and bacteriocin | |
CN102326678B (en) | Penta-composite probiotic powder preparation and preparation method thereof | |
CN102660478B (en) | Lactobacillus salivarius and freeze-dried preparation thereof and application of freeze-dried preparation | |
CN101671638A (en) | New strain of bifidobacterium and fermentative preparation method and application thereof | |
CN112011481A (en) | Lactobacillus reuteri for preventing and treating bacterial diarrhea of livestock and poultry and application thereof | |
CN113907208B (en) | Feed additive for preventing diarrhea of piglets, and preparation method and application thereof | |
CN1831114A (en) | Manure enterococcin strain and use thereof | |
Li et al. | Effects of fermented feed on growth performance, nutrient metabolism and cecal microflora of broilers | |
CN102907585A (en) | Probiotics and vitamin premix and mixture for middle pig | |
CN105199978A (en) | Bacillus coagulans preparation for livestock breeding and preparation method thereof | |
CN105219682B (en) | A kind of bacillus licheniformis of substitute antibiotics feed addictive and its application | |
CN101028037A (en) | Feed additive for improving fowl and beast entric immune and its production | |
CN109874920A (en) | A kind of composite microbial feed additive and preparation method thereof | |
CN111728081B (en) | Composite bacteria fermentation liquor for feed additive and preparation method thereof | |
CN109652334A (en) | A kind of complex microbial inoculum and its preparation method and application | |
CN113615766A (en) | Preparation and application of composite plant extract and probiotic biological fermentation feed | |
CN102093966B (en) | Mink-derived Lactobacillus plantarum strain MDL1118 and application thereof | |
CN110016443B (en) | Lactobacillus reuteri and application thereof in production of selenium-rich eggs | |
CN114052116B (en) | Probiotic plant extract compound biological agent and preparation method and application thereof | |
CN1162089C (en) | Microecological regulator for animal and fowl | |
US20240000864A1 (en) | Bacillus coagulans having blood glucose reduction efficacy, and application thereof | |
CN1615727A (en) | Oligose fodder additive and its producing method | |
CN101028038A (en) | Yishengkang |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |